Vitamin D supplementation can decrease circulating 27-hydroxycholesterol in breast cancer patients, likely by CYP27A1 inhibition. This suggests a new and additional modality by which vitamin D can inhibit ER+ breast cancer growth; a larger study is needed for verification. Here, CYP27A1 is linked to breast carcinoma.